Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Clin Infect Dis. 2022 Apr 9;74(7):1303-1312. doi: 10.1093/cid/ciab757.
Cefiderocol is a novel injectable siderophore cephalosporin that hijacks the bacterial iron transport machinery to facilitate cell entry and achieve high periplasmic concentrations. It has broad in vitro activity against gram-negative bacteria, including multidrug-resistant (MDR) organisms such as carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii. It was approved by the US Food and Drug Administration for the treatment of complicated urinary tract infections and nosocomial pneumonia based on clinical trials that demonstrated noninferiority to comparators. In this review, we summarize the available in vitro and clinical data, including recent evidence from 2 phase 3 clinical trials (APEKS-NP and CREDIBLE-CR), and discuss the place of cefiderocol in the clinician's armamentarium against MDR gram-negative infections.
头孢地尔可洛是一种新型的注射用铁载体头孢菌素，它劫持细菌的铁运输机制，促进细胞进入并在周质中达到高浓度。它对革兰氏阴性菌具有广泛的体外活性，包括多药耐药（MDR）的生物体，如耐碳青霉烯肠杆菌科、耐碳青霉烯铜绿假单胞菌和鲍曼不动杆菌。它基于临床试验获得批准，这些临床试验表明其与对照药物相比不劣效，用于治疗复杂尿路感染和医院获得性肺炎。在这篇综述中，我们总结了现有的体外和临床数据，包括最近来自 2 项 3 期临床试验（APEKS-NP 和 CREDIBLE-CR）的证据，并讨论了头孢地尔可洛在对抗 MDR 革兰氏阴性感染的临床医生武器库中的地位。
